Report cover image

Global Osimertinib Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 199 Pages
SKU # APRC20556377

Description

Summary

According to APO Research, the global Osimertinib market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Osimertinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Osimertinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Osimertinib market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Osimertinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Osimertinib market include Beacon Pharma, Drug International, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited and AstraZeneca, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Osimertinib, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Osimertinib, also provides the sales of main regions and countries. Of the upcoming market potential for Osimertinib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Osimertinib sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Osimertinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Osimertinib sales, projected growth trends, production technology, application and end-user industry.

Osimertinib Segment by Company

Beacon Pharma
Drug International
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
AstraZeneca
Osimertinib Segment by Type

80mg*30 Tablets
80mg*10 Tablets
40mg*30 Tablets
40mg*10 Tablets
Osimertinib Segment by Application

Locally Advanced NSCLC
Metastatic NSCLC
Others
Osimertinib Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Osimertinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Osimertinib market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Osimertinib significant trends, drivers, influence factors in global and regions.
6. To analyze Osimertinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osimertinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osimertinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osimertinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Osimertinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Osimertinib industry.
Chapter 3: Detailed analysis of Osimertinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Osimertinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Osimertinib in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Osimertinib Sales Value (2020-2031)
1.2.2 Global Osimertinib Sales Volume (2020-2031)
1.2.3 Global Osimertinib Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Osimertinib Market Dynamics
2.1 Osimertinib Industry Trends
2.2 Osimertinib Industry Drivers
2.3 Osimertinib Industry Opportunities and Challenges
2.4 Osimertinib Industry Restraints
3 Osimertinib Market by Company
3.1 Global Osimertinib Company Revenue Ranking in 2024
3.2 Global Osimertinib Revenue by Company (2020-2025)
3.3 Global Osimertinib Sales Volume by Company (2020-2025)
3.4 Global Osimertinib Average Price by Company (2020-2025)
3.5 Global Osimertinib Company Ranking (2023-2025)
3.6 Global Osimertinib Company Manufacturing Base and Headquarters
3.7 Global Osimertinib Company Product Type and Application
3.8 Global Osimertinib Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Osimertinib Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Osimertinib Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Osimertinib Market by Type
4.1 Osimertinib Type Introduction
4.1.1 80mg*30 Tablets
4.1.2 80mg*10 Tablets
4.1.3 40mg*30 Tablets
4.1.4 40mg*10 Tablets
4.2 Global Osimertinib Sales Volume by Type
4.2.1 Global Osimertinib Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Osimertinib Sales Volume by Type (2020-2031)
4.2.3 Global Osimertinib Sales Volume Share by Type (2020-2031)
4.3 Global Osimertinib Sales Value by Type
4.3.1 Global Osimertinib Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Osimertinib Sales Value by Type (2020-2031)
4.3.3 Global Osimertinib Sales Value Share by Type (2020-2031)
5 Osimertinib Market by Application
5.1 Osimertinib Application Introduction
5.1.1 Locally Advanced NSCLC
5.1.2 Metastatic NSCLC
5.1.3 Others
5.2 Global Osimertinib Sales Volume by Application
5.2.1 Global Osimertinib Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Osimertinib Sales Volume by Application (2020-2031)
5.2.3 Global Osimertinib Sales Volume Share by Application (2020-2031)
5.3 Global Osimertinib Sales Value by Application
5.3.1 Global Osimertinib Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Osimertinib Sales Value by Application (2020-2031)
5.3.3 Global Osimertinib Sales Value Share by Application (2020-2031)
6 Osimertinib Regional Sales and Value Analysis
6.1 Global Osimertinib Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Osimertinib Sales by Region (2020-2031)
6.2.1 Global Osimertinib Sales by Region: 2020-2025
6.2.2 Global Osimertinib Sales by Region (2026-2031)
6.3 Global Osimertinib Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Osimertinib Sales Value by Region (2020-2031)
6.4.1 Global Osimertinib Sales Value by Region: 2020-2025
6.4.2 Global Osimertinib Sales Value by Region (2026-2031)
6.5 Global Osimertinib Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Osimertinib Sales Value (2020-2031)
6.6.2 North America Osimertinib Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Osimertinib Sales Value (2020-2031)
6.7.2 Europe Osimertinib Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Osimertinib Sales Value (2020-2031)
6.8.2 Asia-Pacific Osimertinib Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Osimertinib Sales Value (2020-2031)
6.9.2 South America Osimertinib Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Osimertinib Sales Value (2020-2031)
6.10.2 Middle East & Africa Osimertinib Sales Value Share by Country, 2024 VS 2031
7 Osimertinib Country-level Sales and Value Analysis
7.1 Global Osimertinib Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Osimertinib Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Osimertinib Sales by Country (2020-2031)
7.3.1 Global Osimertinib Sales by Country (2020-2025)
7.3.2 Global Osimertinib Sales by Country (2026-2031)
7.4 Global Osimertinib Sales Value by Country (2020-2031)
7.4.1 Global Osimertinib Sales Value by Country (2020-2025)
7.4.2 Global Osimertinib Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Osimertinib Sales Value Growth Rate (2020-2031)
7.5.2 USA Osimertinib Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Osimertinib Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Osimertinib Sales Value Growth Rate (2020-2031)
7.6.2 Canada Osimertinib Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Osimertinib Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Osimertinib Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Osimertinib Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Osimertinib Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Osimertinib Sales Value Growth Rate (2020-2031)
7.8.2 Germany Osimertinib Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Osimertinib Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Osimertinib Sales Value Growth Rate (2020-2031)
7.9.2 France Osimertinib Sales Value Share by Type, 2024 VS 2031
7.9.3 France Osimertinib Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Osimertinib Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Osimertinib Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Osimertinib Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Osimertinib Sales Value Growth Rate (2020-2031)
7.11.2 Italy Osimertinib Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Osimertinib Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Osimertinib Sales Value Growth Rate (2020-2031)
7.12.2 Spain Osimertinib Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Osimertinib Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Osimertinib Sales Value Growth Rate (2020-2031)
7.13.2 Russia Osimertinib Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Osimertinib Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Osimertinib Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Osimertinib Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Osimertinib Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Osimertinib Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Osimertinib Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Osimertinib Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Osimertinib Sales Value Growth Rate (2020-2031)
7.16.2 China Osimertinib Sales Value Share by Type, 2024 VS 2031
7.16.3 China Osimertinib Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Osimertinib Sales Value Growth Rate (2020-2031)
7.17.2 Japan Osimertinib Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Osimertinib Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Osimertinib Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Osimertinib Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Osimertinib Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Osimertinib Sales Value Growth Rate (2020-2031)
7.19.2 India Osimertinib Sales Value Share by Type, 2024 VS 2031
7.19.3 India Osimertinib Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Osimertinib Sales Value Growth Rate (2020-2031)
7.20.2 Australia Osimertinib Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Osimertinib Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Osimertinib Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Osimertinib Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Osimertinib Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Osimertinib Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Osimertinib Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Osimertinib Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Osimertinib Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Osimertinib Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Osimertinib Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Osimertinib Sales Value Growth Rate (2020-2031)
7.24.2 Chile Osimertinib Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Osimertinib Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Osimertinib Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Osimertinib Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Osimertinib Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Osimertinib Sales Value Growth Rate (2020-2031)
7.26.2 Peru Osimertinib Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Osimertinib Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Osimertinib Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Osimertinib Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Osimertinib Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Osimertinib Sales Value Growth Rate (2020-2031)
7.28.2 Israel Osimertinib Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Osimertinib Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Osimertinib Sales Value Growth Rate (2020-2031)
7.29.2 UAE Osimertinib Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Osimertinib Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Osimertinib Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Osimertinib Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Osimertinib Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Osimertinib Sales Value Growth Rate (2020-2031)
7.31.2 Iran Osimertinib Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Osimertinib Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Osimertinib Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Osimertinib Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Osimertinib Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Beacon Pharma
8.1.1 Beacon Pharma Comapny Information
8.1.2 Beacon Pharma Business Overview
8.1.3 Beacon Pharma Osimertinib Sales, Value and Gross Margin (2020-2025)
8.1.4 Beacon Pharma Osimertinib Product Portfolio
8.1.5 Beacon Pharma Recent Developments
8.2 Drug International
8.2.1 Drug International Comapny Information
8.2.2 Drug International Business Overview
8.2.3 Drug International Osimertinib Sales, Value and Gross Margin (2020-2025)
8.2.4 Drug International Osimertinib Product Portfolio
8.2.5 Drug International Recent Developments
8.3 Everest Pharmaceuticals
8.3.1 Everest Pharmaceuticals Comapny Information
8.3.2 Everest Pharmaceuticals Business Overview
8.3.3 Everest Pharmaceuticals Osimertinib Sales, Value and Gross Margin (2020-2025)
8.3.4 Everest Pharmaceuticals Osimertinib Product Portfolio
8.3.5 Everest Pharmaceuticals Recent Developments
8.4 Incepta Pharmaceuticals Limited
8.4.1 Incepta Pharmaceuticals Limited Comapny Information
8.4.2 Incepta Pharmaceuticals Limited Business Overview
8.4.3 Incepta Pharmaceuticals Limited Osimertinib Sales, Value and Gross Margin (2020-2025)
8.4.4 Incepta Pharmaceuticals Limited Osimertinib Product Portfolio
8.4.5 Incepta Pharmaceuticals Limited Recent Developments
8.5 AstraZeneca
8.5.1 AstraZeneca Comapny Information
8.5.2 AstraZeneca Business Overview
8.5.3 AstraZeneca Osimertinib Sales, Value and Gross Margin (2020-2025)
8.5.4 AstraZeneca Osimertinib Product Portfolio
8.5.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Osimertinib Value Chain Analysis
9.1.1 Osimertinib Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Osimertinib Sales Mode & Process
9.2 Osimertinib Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Osimertinib Distributors
9.2.3 Osimertinib Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.